Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	2 shs
GMAB Genmab A/S	$20.59 +0.2%	$20.47	$17.24 ▼ $30.41	$13.63B	1.07	1.05 million shs	715,774 shs
ITCI Intra-Cellular Therapies	$131.87	$131.16	$64.09 ▼ $131.98	$14.05B	0.69	1.46 million shs	N/A
TEVA Teva Pharmaceutical Industries	$14.88 +1.1%	$15.23	$12.47 ▼ $22.80	$15.65B	0.72	9.93 million shs	6.57 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	+0.62%
GMAB Genmab A/S	0.00%	+2.74%	+2.23%	-2.56%	-27.68%
ITCI Intra-Cellular Therapies	0.00%	0.00%	+0.09%	+3.55%	+80.35%
TEVA Teva Pharmaceutical Industries	0.00%	+9.37%	-4.15%	-31.54%	+14.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	4.444 of 5 stars	4.3	5.0	0.0	0.0	3.5	0.0	3.1
ITCI Intra-Cellular Therapies	2.2638 of 5 stars	1.1	3.0	0.0	4.5	1.1	1.7	0.6
TEVA Teva Pharmaceutical Industries	3.1106 of 5 stars	3.4	5.0	0.8	0.0	2.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	2.00	Hold	$65.00	0.05% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	90.22% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	57.45% Upside

Current Analyst Ratings Breakdown

Latest ALPN, TEVA, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
3/11/2025	GMAB Genmab A/S	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00
2/24/2025	ITCI Intra-Cellular Therapies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$140.00 ➝ $132.00
2/21/2025	ITCI Intra-Cellular Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/13/2025	GMAB Genmab A/S	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/13/2025	GMAB Genmab A/S	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$27.00
2/11/2025	GMAB Genmab A/S	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
GMAB Genmab A/S	$21.53B	0.63	$1.39 per share	14.80	$8.04 per share	2.56
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
TEVA Teva Pharmaceutical Industries	$16.54B	1.02	$2.95 per share	5.05	$4.75 per share	3.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
GMAB Genmab A/S	$1.14B	$1.74	11.83	11.57	2.65	36.30%	16.78%	13.79%	5/8/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.66	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest ALPN, TEVA, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.26	N/A	N/A	N/A	$5.17 billion	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	N/A	N/A	N/A	$3.99 billion	N/A
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.79%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
GMAB Genmab A/S	N/A	5.25	5.24
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	Optionable
GMAB Genmab A/S	1,660	661.97 million	651.58 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

ALPN, TEVA, ITCI, and GMAB Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Barclays PLC

April 27 at 3:54 AM | marketbeat.com

Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $23.43

April 26 at 1:45 AM | americanbankingnews.com

RBF Capital LLC Sells 40,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 25 at 6:42 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by Analysts

April 25 at 4:26 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by BlackBarn Capital Partners LP

April 24 at 7:29 AM | marketbeat.com

300,000 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Diadema Partners LP

April 24 at 7:16 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Slate Path Capital LP's 9th Largest Position

April 24 at 7:10 AM | marketbeat.com

Eversept Partners LP Sells 992,513 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 24 at 7:08 AM | marketbeat.com

Continental Advisors LLC Sells 20,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 24 at 6:50 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Invests $6.01 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 23, 2025 | marketbeat.com

CANADA LIFE ASSURANCE Co Raises Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 23, 2025 | marketbeat.com

Teachers Retirement System of The State of Kentucky Invests $37.69 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 22, 2025 | marketbeat.com

Capital International Investors Has $58.73 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 22, 2025 | marketbeat.com

Beck Mack & Oliver LLC Sells 36,160 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 21, 2025 | marketbeat.com

JB Chemicals & Pharma receives USFDA approval for Bisoprolol Tablets

April 21, 2025 | business-standard.com

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

April 21, 2025 | fool.com

Gamco Investors INC. ET AL Reduces Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 20, 2025 | marketbeat.com

39,413 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by CreativeOne Wealth LLC

April 20, 2025 | marketbeat.com

Altshuler Shaham Ltd Has $4.36 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19, 2025 | marketbeat.com

Marshall Wace LLP Purchases 2,410,420 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19, 2025 | marketbeat.com

Gabelli Funds LLC Acquires 183,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, TEVA, ITCI, and GMAB Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Genmab A/S NASDAQ:GMAB

$20.59 +0.05 (+0.24%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$21.24 +0.65 (+3.18%)

As of 04/25/2025 04:58 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$14.88 +0.16 (+1.09%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$14.86 -0.02 (-0.10%)

As of 04/25/2025 07:48 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time